Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC2R | Q01718 | 6/20 | 0.54 |
| ▸ | SSTR4 | P31391 | 10/20 | 0.50 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30090945 | 1.00 | MC2R (0.54) | MC2RSSTR4SSTR1USP30NTRK1 | |
| SCHEMBL31162221 | 1.00 | MC2R (0.54) | MC2RSSTR4SSTR1USP30NTRK1 | |
| SCHEMBL31077853 | 0.85 | USP30 (0.59) | MC2RUSP30 | |
| SCHEMBL31077886 | 0.84 | MC2R (0.63) | MC2RSSTR4SSTR1 | |
| SCHEMBL23201602 | 0.84 | IRAK4 (0.56) | MC2RUSP30NTRK1IRAK4 | |
| SCHEMBL31077928 | 0.82 | DGAT2 (0.49) | MC2RNTRK1IRAK4 | |
| SCHEMBL29963597 | 0.78 | MC2R (0.71) | MC2RSSTR4SSTR1 | |
| SCHEMBL29963087 | 0.78 | MC2R (0.71) | MC2RSSTR4SSTR1 | |
| SCHEMBL29963613 | 0.78 | MC2R (0.71) | MC2RSSTR4SSTR1 | |
| SCHEMBL29963455 | 0.78 | MC2R (0.71) | MC2RSSTR4SSTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479825-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2025-11-25 | — | — | US | disclosed |
| US-20230015914-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479825-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | MC2R 3/4885SSTR4 92/4885SSTR1 81/4885 |
| US-20230015914-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC3R, MC1R, MC2R | MC2R 3/4885SSTR4 92/4885SSTR1 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.